Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (February 2011)
13 slides from Somnomed's investor presentation, Feb 28, 2011
Slide 1: For personal use only
For personal use only This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially fr
Slide 2: For personal use only
For personal use only 1 2 3 4 Financial Overview US Medicare Product Highlights by Region DME MAC’s Development 2nd Half FY 2011 ruling vs. FY 2010 © SomnoMed 2011 2
Slide 3: Financial Highlights
Financial Highlights 1st Half FY 2011 vs. For personal use only 1st Half FY 2010 Sales SomnoDent Successful Gross Group EBITDA revenue Apnea unit soft launch Margin operating sales and improved to profit before + 48% to + 20% to feedback of Corporate/ 0.39m + 25% to 64% A$ 6.0m Bruxism compared to R
Slide 4: Volume Growth
For personal use only Volume Growth Unit contribution per Region CAGR Units 64% 1st Half 10/11 Units sold per quarter © SomnoMed 2011 4
Slide 5: For personal use only
For personal use only $6,000,000 $5,000,000 $4,000,000 A$ $3,000,000 $2,000,000 $1,000,000 $0 Years © SomnoMed 2011 5
Slide 6: Financial Summary ($000's)
For personal use only 10/11 09/10 08/09 07/08 06/07 Financial Summary ( $000's ) 1st H 1st H 1st H 1st H 1st H Units 11,450 9,140 5,475 2,916 1,870 Revenue 5,975 4,989 3,180 1,497 1,104 Gross Margin 3,825 2,847 1,655 728 486 Gross Margin% 64.0% 57.1% 52.0% 48.6% 44.0% Operating profit / ( loss) befo
Slide 7: Europe
For personal use only Europe Significant growth volume of more than 122% Nordic and Central European region are key drivers Favourable OAT reimbursement in Sweden, France, Belgium and Holland High barrier of entry for non- medical oral appliances © SomnoMed 2011 7
Slide 8: Japan; Australia/New Zealand/Asia
For personal use only Japan Growing number of educated and qualified SomnoMed dentists Moderate growth volume due to low- GHI reimbursement Australia/ New Zealand/ Asia Continuing market leadership with SomnoDent Modest growth due to non-reimbursement of OSA treatment Positive response to the market
Slide 9: North America
For personal use only North America Record unit sales in Q2 Positive Medicare CMS ruling for Oral Appliance Treatment (OAT) New VP Marketing & Academy with strong focus on Medical New VP Sales and restructure of Medical/Dental sales territories © SomnoMed 2011 9
Slide 10: Medicare coverage of oral appliances for OSA
For personal use only | Custom fabricated oral appliance (E0486) used to treat Obstructive Sleep Apnea (OSA) is covered if certain criteria are met: Key details: Treatment of OSA up to an AHI/RDI of 30 events/hour (mild to moderate) are covered, without the precondition that the Patient is deemed un
Slide 11: Product development: SomnoDent G2 and MATRIx
For personal use only | Market launch in Q4 of the next generation of the world’s # 1 oral sleep apnea appliance. The SomnoDent G2 will again raise the standard in comfort, compliance and treatment for the patient and the doctor. | Final clinical trial for FDA for market launch in Q4 of SomnoMed MAT
Slide 12: SomnoMed Review - Thank-you
For personal use only SomnoMed®… Review The future is now... Thank-you © SomnoMed 2011 12
Slide 13: Contacts
For personal use only Contacts: Chairman Address Telephone Dr Peter Neustadt Level 3, +61 (0)2 9467 0400 20 Clarke Street Chief Executive Officer Crows Nest NSW 2065 Website Mr Ralf Barschow Australia www.somnomed.com.au © SomnoMed 2011 13